Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A CUE hints at tumor resistance.

× No keyword cloud information.

12 in total

Review 1. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.

Authors: Suleiman Massarweh; Rachel Schiff
Journal: Endocr Relat Cancer Date: 2006-12 Impact factor: 5.678

Review 2. Biological determinants of endocrine resistance in breast cancer.

Authors: Elizabeth A Musgrove; Robert L Sutherland
Journal: Nat Rev Cancer Date: 2009-09 Impact factor: 60.716

3. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Authors: Chad A Livasy; Gamze Karaca; Rita Nanda; Maria S Tretiakova; Olufunmilayo I Olopade; Dominic T Moore; Charles M Perou
Journal: Mod Pathol Date: 2006-02 Impact factor: 7.842

4. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer.

Authors: Xin Pan; Tao Zhou; Yan-Hong Tai; Chenguang Wang; Jie Zhao; Yuan Cao; Yuan Chen; Pei-Jing Zhang; Ming Yu; Cheng Zhen; Rui Mu; Zhao-Fang Bai; Hui-Yan Li; Ai-Ling Li; Bing Liang; Zhao Jian; Wei-Na Zhang; Jiang-Hong Man; Yan-Fei Gao; Wei-Li Gong; Li-Xin Wei; Xue-Min Zhang
Journal: Nat Med Date: 2011-05-15 Impact factor: 53.440

Review 5. Estrogen receptor mutations and changes in downstream gene expression and signaling.

Authors: Ines Barone; Lauren Brusco; Suzanne A W Fuqua
Journal: Clin Cancer Res Date: 2010-04-28 Impact factor: 12.531

Review 6. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.

Authors: Grazia Arpino; Lisa Wiechmann; C Kent Osborne; Rachel Schiff
Journal: Endocr Rev Date: 2008-01-23 Impact factor: 19.871

7. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer.

Authors: Jian-Jun Zhao; Jianhong Lin; Hua Yang; William Kong; Lili He; Xu Ma; Domenico Coppola; Jin Q Cheng
Journal: J Biol Chem Date: 2008-09-12 Impact factor: 5.157

8. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.

Authors: Liang Shi; Bin Dong; Zhongwu Li; Yunwei Lu; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Tie Fan; Benyao Lin; Zhaoyi Wang; Yuntao Xie
Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544

9. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.

Authors: Antoni Hurtado; Kelly A Holmes; Timothy R Geistlinger; Iain R Hutcheson; Robert I Nicholson; Myles Brown; Jie Jiang; William J Howat; Simak Ali; Jason S Carroll
Journal: Nature Date: 2008-11-12 Impact factor: 49.962

10. CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome.

Authors: Pei-Jing Zhang; Jie Zhao; Hui-Yan Li; Jiang-Hong Man; Kun He; Tao Zhou; Xin Pan; Ai-Ling Li; Wei-Li Gong; Bao-Feng Jin; Qing Xia; Ming Yu; Bei-Fen Shen; Xue-Min Zhang
Journal: EMBO J Date: 2007-03-08 Impact factor: 11.598

3 in total

1. Investigation of discriminant metabolites in tamoxifen-resistant and choline kinase-alpha-downregulated breast cancer cells using 1H-nuclear magnetic resonance spectroscopy.

Authors: Hoe Suk Kim; Lianji Tian; Hyeonjin Kim; Woo Kyung Moon
Journal: PLoS One Date: 2017-06-23 Impact factor: 3.240

2. ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function.

Authors: Igor Bado; Eric Pham; Benjamin Soibam; Fotis Nikolos; Jan-Åke Gustafsson; Christoforos Thomas
Journal: Oncotarget Date: 2018-04-27

3. LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway.

Authors: Maolin Mu; Wanxiang Niu; Xiaoming Zhang; Shanshan Hu; Chaoshi Niu
Journal: Oncogene Date: 2020-09-25 Impact factor: 8.756

3 in total